6-(三氟甲基)吡啶-2-甲酸 | 131747-42-7

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(三氟甲基)吡啶-2-甲酸
• 中文别名: 6-三氟甲基吡啶-2-甲酸；2-羧酸-6-三氟甲基吡啶；6-(三氟甲基吡啶-2-羧酸；6-(三氟甲基)吡啶甲酸
• 英文名称: 6-(trifluoromethyl)pyridine-2-carboxylic acid
• 英文别名: 6-(trifluoromethyl)picolinic acid；6-trifluoromethyl-2-pyridinecarboxylic acid；6-(trifluoromethyl)pyridin-2-carboxylic acid；6‑(trifluoromethyl)picolinic acid
• CAS: 131747-42-7
• 化学式: C₇H₄F₃NO₂
• mdl: MFCD02180819
• 分子量: 191.109
• InChiKey: OKBHXGBLXDNJJD-UHFFFAOYSA-N

物化性质

• 熔点：
  154-158 °C
• 沸点：
  263.0±40.0 °C(Predicted)
• 密度：
  1.484±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R22,R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Trifluoromethyl-6-pyridinecarboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Trifluoromethyl-6-pyridinecarboxylic acid
CAS number: 131747-42-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H4F3NO2
Molecular weight: 191.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (2-Trifluoromethyl-6-pyridinecarboxylic acid)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

6-（三氟甲基）吡啶-2-甲酸是一种有机中间体，可用于制备2-（6-（三氟甲基）吡啶-2-基）乙腈等有机物。

制备

将2-溴-6-三氟甲基吡啶 (1.13 g, 5 mmol)、氰化亚铜 (0.67 g, 7.5 mmol) 和碘化钾 (1.25 g, 7.5 mmol) 悬浮在DMF (15 mL) 中，加热至130℃反应12小时。反应混合物倒入冰水 (100 mL)和乙酸乙酯 (50 mL) 的混合溶剂中。滤去固体后，用乙酸乙酯萃取 (50 mL*3)，合并有机相并用饱和食盐水洗涤，再用无水硫酸镁干燥。浓缩得到淡黄色油状物2-氰基-6-三氟甲基吡啶 (0.95 g)。

将2-氰基-6-三氟甲基吡啶 (0.95 g) 和浓盐酸HCl (37%，15 mL) 加热回流2小时。冷却后，过滤得到白色固体6-（三氟甲基）吡啶-2-甲酸 (0.70 g, 74%)。

反应信息

• 作为反应物：
  描述：

  6-(三氟甲基)吡啶-2-甲酸 在 氯化亚砜 、 乙醇 、 五氯化磷 、 sodium 、 碳酸氢钠 作用下， 以 四氢呋喃 、 丙酮 、 三氯氧磷 为溶剂， 反应 25.17h， 生成 AG221甲磺酸盐
  参考文献：
  名称：

  [EN] CRYSTALLINE FORMS OF THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF
  [FR] FORMES CRISTALLINES DE COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET UTILISATION ASSOCIÉE

  摘要：

  提供了2-甲基-1-[(4-[6-(三氟甲基)吡啶-2-基]-6-{[2-(三氟甲基)吡啶-4-基]氨基}-1,3,5-三嗪-2-基)氨基]丙醇(COMPOUND 3)、2-甲基-1-[(4-[6-(三氟甲基)吡啶-2-基]-6-{[2-(三氟甲基)吡啶-4-基]氨基}-1,3,5-三嗪-2-基)氨基]丙醇甲磺酸盐(COMPOUND 1)的结晶形式及其用途。

  公开号：

  WO2015018060A1
• 作为产物：
  描述：

  二氧化碳 在 正丁基锂 、 盐酸 作用下， 以 乙醚 、 正己烷 、 水 为溶剂， 反应 0.25h， 以35%的产率得到6-(三氟甲基)吡啶-2-甲酸
  参考文献：
  名称：

  Cyclic derivatives as modulators of chemokine receptor activity

  摘要：

  当前申请描述了MCP-1的调节剂，其化学公式为(I):或其药用可接受的盐形式，用于治疗类风湿性关节炎、多发性硬化症、动脉粥样硬化和哮喘。

  公开号：

  US20050054627A1

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20190151295A1

  公开（公告）日：2019-05-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为白细胞介素-1受体相关激酶4（IRAK-4；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物，另一端结合目标蛋白的部分，使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
• [EN] COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK<br/>[FR] COMBINAISONS D'INHIBITEURS DE L'IRAK4 À L'AIDE D'INHIBITEURS DE LA BTK
  申请人：BAYER PHARMA AG

  公开号：WO2016174183A1

  公开（公告）日：2016-11-03

  The present application relates to novel combinations of at least two components, component A and component B: · component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; · component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, · one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.

  本申请涉及至少两种组分的新型组合，组分A和组分B：·组分A是根据本文所定义的式(I)的IRAK4抑制化合物，或其对映体、对映异构体、代谢物、盐、溶剂合物或其盐的溶剂合物；·组分B是BTK抑制化合物，或其药学上可接受的盐；以及，可选地，·一种或多种组分C，它们是药用产品；其中上述定义的化合物A和B中的一种或两种可选择地存在于用于治疗和/或预防疾病的制剂中，准备用于同时、分开或顺序给药，用于治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防子宫内膜异位症、淋巴瘤、黄斑变性、慢性阻塞性肺病、肿瘤性疾病和牛皮癣。
• Organocatalytic decarboxylative alkylation of <i>N</i>-hydroxy-phthalimide esters enabled by pyridine-boryl radicals
  作者：Liuzhou Gao、Guoqiang Wang、Jia Cao、Dandan Yuan、Cheng Xu、Xuewen Guo、Shuhua Li

  DOI：10.1039/c8cc06152a

  日期：——

  The decarboxylative alkylation of N-hydroxyphthalimide (NHPI) based reactive esters with olefins has been achieved via an organocatalytic strategy. Control experiments and density functional theory calculations suggest that these reactions involve a boryl-radical mediated decarboxylation pathway, which is different from the single electron transfer involved in decarboxylative alkylation reactions reported

  N-羟基邻苯二甲酰亚胺（NHPI）基反应性酯与烯烃的脱羧烷基化已通过有机催化策略实现。对照实验和密度泛函理论计算表明，这些反应涉及硼基自由基介导的脱羧途径，该途径不同于先前报道的脱羧烷基化反应中涉及的单电子转移。这种无金属的脱羧烷基化反应具有良好的功能相容性，并且通过烷基和芳基羧酸衍生物的转化说明了广泛的底物范围。
• The Direct Metalation and Subsequent Functionalization of Trifluoromethyl-Substituted Pyridines and Quinolines
  作者：Manfred Schlosser、Marc Marull

  DOI：10.1002/ejoc.200390216

  日期：2003.4

  nucleophilic addn. and ensuing decompn. whatever the base. Depending on the reaction conditions, 2-(trifluoromethyl)quinoline displays reactivity toward lithium reagents at its 3-, 4-, or 8- positions, 3-(trifluoromethyl)quinolines at the 2- or 4-positions, and 4-(trifluoromethyl)quinoline at the 2- or 3-positions. It was therefore possible to prep. four trifluoromethyl-substituted pyridinecarboxylic acids

  根据试剂的选择，2-(三氟甲基)吡啶可以被选择性地金属化并随后在3-位或6-位被羧化或以其他方式官能化。“可选的位点选择性”也可以用 4-(三氟甲基)吡啶来实现，它可以在 2-位或 3-位去质子化。相反，3-（三氟甲基）吡啶发生亲核加成。和随之而来的解体。不管是什么基地。根据反应条件，2-（三氟甲基）喹啉在其 3-、4- 或 8- 位对锂试剂显示反应性，在 2-或 4-位对 3-（三氟甲基）喹啉和 4-（三氟甲基）喹啉)喹啉在 2 位或 3 位。因此可以进行准备。四种三氟甲基取代的吡啶羧酸和六种三氟甲基取代的喹啉羧酸，区域异构未受污染，并且以最直接的方式。[在 SciFinder (R) 上]